In 2015, CIRM launched an ambitious Strategic Plan built around six major goals. Together, those goals aimed to accelerate the development of stem cell and regenerative medicine therapies for patients with unmet medical needs.
One of those priorities focused on the earliest stage of research: Discover.
While clinical trials often attract the most attention, every successful therapy begins years earlier with a scientific idea. Before a treatment reaches patients, researchers must first determine whether the underlying concept actually works.
That journey starts with discovery.
Why Discovery Research Matters
Discovery research forms the foundation of the regenerative medicine pipeline.
At this stage, researchers explore how stem cells work, investigate disease mechanisms, and test new ideas that could eventually lead to therapies or medical devices.
The goal is not simply to generate knowledge.
The goal is to identify findings with the potential to advance toward real-world solutions for patients.
Promising projects can move into translational research, where scientists refine and test therapeutic approaches. The most successful programs may then advance into clinical development and human trials.
Without a strong discovery program, that pipeline eventually runs dry.
Building the Pipeline for Future Therapies
When CIRM developed its Strategic Plan, the agency wanted to create a continuous pathway from discovery through clinical testing.
To accomplish that, CIRM established a bold goal:
Introduce 50 new therapeutic or device candidates into development.
Importantly, that target meant more than simply funding 50 research projects.
Many early-stage studies explore ideas that ultimately prove ineffective. That is a normal and necessary part of science.
CIRM wanted to support projects that produced something more tangible: a therapeutic or device candidate ready to advance into the next stage of development.
In other words, the agency focused on projects with the potential to move closer to patients.
Turning Scientific Ideas Into Therapeutic Candidates
Discovery research carries inherent risk.
Scientists often begin with promising hypotheses, but many do not survive rigorous testing.
That is why advancing a project from basic research to a development-ready candidate represents a meaningful achievement.
By the end of the Strategic Plan period, CIRM-supported researchers had generated 46 therapeutic or device candidates that advanced, or were ready to advance, into later stages of development.
The agency narrowly missed its goal of 50 candidates.
Even so, the outcome reflects substantial progress.
Those 46 candidates now form a pipeline of potential therapies and technologies that may continue moving toward clinical testing and, ultimately, patients.
Measuring Success Beyond the Numbers
Not every candidate will become an FDA-approved therapy.
Drug and device development remains challenging, and many promising programs will encounter scientific, clinical, or regulatory obstacles.
However, discovery research creates opportunity.
Each successful candidate represents a new possibility for addressing diseases that lack effective treatments.
Without those early investments, future clinical trials would never begin.
The discovery stage may receive less public attention than later phases of development, but it remains one of the most important parts of the entire research ecosystem.
Looking Ahead
The Discover goal demonstrated the importance of investing in early-stage science while maintaining a clear focus on patient impact.
The 46 candidates that emerged from CIRM-supported discovery programs reflect years of work by researchers across California. They also illustrate how strategic funding can transform promising ideas into tangible development programs.
With the passage of Proposition 14, CIRM gained the opportunity to continue supporting that pipeline.
The agency can now help advance many of these candidates through translational studies, clinical development, and, potentially, toward therapies that improve patients’ lives.
That is the purpose of discovery research: not simply to understand biology, but to use that knowledge to create a better future for patients.
